Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, Maral DerSarkissian, PhD, Mei Sheng Duh, MPH, ScD, Marie-Hélène Lafeuille, MA, George Posner, BA, Stephen Ralston, PhD, Erin Zagadailov, PharmD, MS, Abbie Ba-Mancini, MSc, MBA, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 5599.

https://doi.org/10.1182/blood.V130.Suppl_1.5599.5599

Published: 2017

Journal Articles

A Retrospective Chart Review to Assess Burden of Illness Among Patients with Severe Aplastic Anemia with Insufficient Response to Immunosuppressive Therapy

Regis Peffault De Latour, MD PhD, Lynn Huynh, Jasmina I. Ivanova, Todor Totev, BSc, Mehmet Bilginsoy, BA, Joseph H. Antin, MD, Anuja Roy, PhD, Mei Sheng Duh, MPH, ScD

Blood (2017) 130 (Supplement 1): 678.

https://doi.org/10.1182/blood.V130.Suppl_1.678.678

Published: 2017

Journal Articles

Treatment Characteristics and Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Second-Line Nilotinib or Dasatinib: A Multi-Country Retrospective Chart Review Study

Jorge E. Cortes, MD, Lynn Huynh, Estella Mendelson, PhD, Patricia Brandt, PhD, Darshan Dalal, MPH, MD PhD, Maral Dersarkissian, PhD, Diego Cortina, MD MSc, Sahil Narkhede, BA, Mei Sheng Duh, MPH, ScD

Blood (2017) 130 (Supplement 1): 2897.

https://doi.org/10.1182/blood.V130.Suppl_1.2897.2897

Published: 2017

Journal Articles

Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States

Elliott P. Vichinsky, MD, Janet Kwiatkowski, MD, Patricia J. Giardina, MD, Carole Paley, MD, Francis Vekeman, MA, Wendy Y. Cheng, MPH, MPhil, Joseph Damron, BA, Nora McCormick, MSc, Medha Sasane, PhDBPharm,MS, Ying Qiu, PhD, Mei Sheng Duh, MPH, ScD, Alexis A. Thompson, MD

Blood (2015) 126 (23): 3279.

https://doi.org/10.1182/blood.V126.23.3279.3279

Published: 2015

Journal Articles

Subcutaneous (SQ) Bortezomib (BTZ) in Patients (Pts) with Relapsed Mantle Cell Lymphoma (MCL): Retrospective, Observational Study of Treatment Patterns and Outcomes in US Community Oncology Practices

Alan P Skarbnik, MD, Esprit Ma, MPH, Marie-Hélène Lafeuille, MA, Jonathan Fortier, MA, Tatyana Feldman, MD, Mei Sheng Duh, MPH, ScD, Yvette Ng, MS, MBA, Helgi van de Velde, MD PhD, Edward Dow, MD, Liviu Niculescu, MD, Vijayveer Bonthapally, PhD, Andre Goy, MD MS

Blood (2014) 124 (21): 1740.

https://doi.org/10.1182/blood.V124.21.1740.1740

Published: 2014

Journal Articles

Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM)

Blood (2013) 122 (21): 3178.

https://doi.org/10.1182/blood.V122.21.3178.3178

Published: 2013

Journal Articles

Age-Related Iron Chelation Utilization and Healthcare Costs in Patients with Sickle Cell Disease (SCD)

Morey A. Blinder, MD, Francis Vekeman, MA, Alex Trahey, BA, Medha Sasane, PhD, Carole S. Paley, MD, Mei Sheng Duh, MPH, ScD

Blood (2011) 118 (21): 338.

https://doi.org/10.1182/blood.V118.21.338.338

Published: 2011

Journal Articles

Age-Related Blood Transfusion Patterns in Patients with Sickle Cell Disease (SCD) and the Association with Sickle Cell Complications

Morey A. Blinder, MD, Francis Vekeman, MA, Alex Trahey, BA, Medha Sasane, PhD, Carole S. Paley, MD, Mei Sheng Duh, MPH, ScD

Blood (2011) 118 (21): 12.

https://doi.org/10.1182/blood.V118.21.12.12

Published: 2011

Journal Articles

Persistence and Compliance of Deferoxamine Versus Deferasirox in Medicaid Patients with Sickle-Cell Disease.

Lanetta B Jordan, MD, MPH, MSPH, Francis Vekeman, MA, Anirban Sengupta, PhD, Mitra Corral, MPH, MS, Amy Guo, PhD, Mei Sheng Duh, MPH, ScD

Blood (2009) 114 (22): 1982.

https://doi.org/10.1182/blood.V114.22.1982.1982

Published: 2009

Journal Articles

Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Blood (2009) 114 (22): 3293.

https://doi.org/10.1182/blood.V114.22.3293.3293

Published: 2009

Journal Articles

Comparison of Infection-Related Hospitalization Risk and Associated Costs among Patients Receiving Sargramostim (Leukine®), Filgrastim (Neupogen®), and Pegfilgrastim (Neulasta®) for Chemotherapy-Induced Neutropenia

Edmond L Toy, PhD, Francis Vekeman, MA, François Laliberté, MA, Bree Dority, PhD, Daniel Perlman, Victoria Barghout, MSPH, Mei Sheng Duh, MPH, ScD, Mark Lawrence Heaney, MD, PhD

Blood (2008) 112 (11): 665.

https://doi.org/10.1182/blood.V112.11.665.665

Published: 2008

Journal Articles

Higher Erythroid Response Rates with Epoetin Alfa Versus Other Agents in Treatment-Naïve Low/Int-1 Myelodysplastic Syndrome Patients: A Comparative Meta-Analysis

Suneel Mundle, PhD, Patrick Lefebvre, MA, Francis Vekeman, MA, Mei Sheng Duh, MPH, ScD, François Laliberté, MA, Ruchi Rastogi, PharmD, Victor Moyo, MD

Blood (2008) 112 (11): 5074.

https://doi.org/10.1182/blood.V112.11.5074.5074

Published: 2008

Journal Articles

An Economic Evaluation of Bortezomib-Based Induction Therapy in Double Transplant Protocols for Newly Diagnosed Multiple Myeloma Patients

Si-Tien Wang, BA, MS, Mei Sheng Duh, MPH, ScD, Hui Huang, PhD, MBA, Leigh Ann White, PhD, Eva Chang, MPH, Dixie-Lee Esseltine, MD, Jing L. Marantz, MD, PhD

Blood (2008) 112 (11): 2386.

https://doi.org/10.1182/blood.V112.11.2386.2386

Published: 2008

NARROW

Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

A Retrospective Chart Review to Assess Burden of Illness Among Patients with Severe Aplastic Anemia with Insufficient Response to Immunosuppressive Therapy

Treatment Characteristics and Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Second-Line Nilotinib or Dasatinib: A Multi-Country Retrospective Chart Review Study

Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States

Subcutaneous (SQ) Bortezomib (BTZ) in Patients (Pts) with Relapsed Mantle Cell Lymphoma (MCL): Retrospective, Observational Study of Treatment Patterns and Outcomes in US Community Oncology Practices

Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM)

Age-Related Iron Chelation Utilization and Healthcare Costs in Patients with Sickle Cell Disease (SCD)

Age-Related Blood Transfusion Patterns in Patients with Sickle Cell Disease (SCD) and the Association with Sickle Cell Complications

Persistence and Compliance of Deferoxamine Versus Deferasirox in Medicaid Patients with Sickle-Cell Disease.

Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Comparison of Infection-Related Hospitalization Risk and Associated Costs among Patients Receiving Sargramostim (Leukine®), Filgrastim (Neupogen®), and Pegfilgrastim (Neulasta®) for Chemotherapy-Induced Neutropenia

Higher Erythroid Response Rates with Epoetin Alfa Versus Other Agents in Treatment-Naïve Low/Int-1 Myelodysplastic Syndrome Patients: A Comparative Meta-Analysis

An Economic Evaluation of Bortezomib-Based Induction Therapy in Double Transplant Protocols for Newly Diagnosed Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only